Uneingeschränkter Zugang

Simvastatin is effective in killing the radioresistant breast carcinoma cells

Bertram Aschenbrenner
Bertram Aschenbrenner
, 
Giulia Negro
Giulia Negro
, 
Dragana Savic
Dragana Savic
, 
Maxim Sorokin
Maxim Sorokin
, 
Anton Buzdin
Anton Buzdin
, 
Ute Ganswindt
Ute Ganswindt
, 
Maja Cemazar
Maja Cemazar
, 
Gregor Sersa
Gregor Sersa
, 
Sergej Skvortsov
Sergej Skvortsov
 und 
Ira Skvortsova
Ira Skvortsova
   | 04. Mai 2021
Radiology and Oncology's Cover Image
Über diesen Artikel
Vorheriger Artikel
Nächster Artikel
Zitieren
Article Category: Research Article
Online veröffentlicht: 04. Mai 2021
Seitenbereich: 305 - 316
Eingereicht: 10. März 2021
Akzeptiert: 02. Apr. 2021
DOI: https://doi.org/10.2478/raon-2021-0020
© 2021 Bertram Aschenbrenner, Giulia Negro, Dragana Savic, Maxim Sorokin, Anton Buzdin, Ute Ganswindt, Maja Cemazar, Gregor Sersa, Sergej Skvortsov, Ira Skvortsova, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Figure 1

Radiation-induced apoptosis in breast carcinoma cells. Radiation sensitivity of the investigated parental and radioresistant breast carcinoma cells was determined using apoptosis assay as described in the section Materials and methods. Grey bars represent parental cells and black bars the radioresistant cells. All experiments were performed at least three times in duplicates; * = p<0.05; ** = p<0.01; *** = p<0.001.
Radiation-induced apoptosis in breast carcinoma cells. Radiation sensitivity of the investigated parental and radioresistant breast carcinoma cells was determined using apoptosis assay as described in the section Materials and methods. Grey bars represent parental cells and black bars the radioresistant cells. All experiments were performed at least three times in duplicates; * = p<0.05; ** = p<0.01; *** = p<0.001.

Figure 2

HMGCR expression in breast carcinoma cells. (A) Constitutive 3-hydroxy-3-methylglutharyl-coenzyme A reductase (HMGCR) expressions in parental and radioresistant breast carcinoma cells. Protein extracts from total cell lysates were subjected to Western blot analysis, and constitutive levels of HMGCR were determined in all investigated breast carcinoma cells; (B) Simvastatin-caused modulation of HMGCR expression in parental and radioresistant breast carcinoma cells was confirmed using Western blot analysis.
HMGCR expression in breast carcinoma cells. (A) Constitutive 3-hydroxy-3-methylglutharyl-coenzyme A reductase (HMGCR) expressions in parental and radioresistant breast carcinoma cells. Protein extracts from total cell lysates were subjected to Western blot analysis, and constitutive levels of HMGCR were determined in all investigated breast carcinoma cells; (B) Simvastatin-caused modulation of HMGCR expression in parental and radioresistant breast carcinoma cells was confirmed using Western blot analysis.

Figure 3

Simvastatin-regulated breast carcinoma cell migration. (A) Wound healing assay was used to determine how simvastatin affected breast carcinoma cell migration. Cell migration was assayed at a magnification of 4x (Lionheart Live Cell Microscope, BioTek, Bad Friedrichshall, Germany). The cell migration rates were determined as a ratio between the gap width at indicated time point and initial gap width at 0 hours; (B) Statistical evaluation of the gap width in breast carcinoma cells. Gap width was measured using the Gen5 (V. 3.08) software and the percentage of the gap width remained after 20 hours of cell incubation in presence of DMSO as a vehicle control or simvastatin (8 μM) was plotted. All experiments were performed at least three times in duplicates; * = p<0.05; ** = p<0.01; *** = p<0.001.
Simvastatin-regulated breast carcinoma cell migration. (A) Wound healing assay was used to determine how simvastatin affected breast carcinoma cell migration. Cell migration was assayed at a magnification of 4x (Lionheart Live Cell Microscope, BioTek, Bad Friedrichshall, Germany). The cell migration rates were determined as a ratio between the gap width at indicated time point and initial gap width at 0 hours; (B) Statistical evaluation of the gap width in breast carcinoma cells. Gap width was measured using the Gen5 (V. 3.08) software and the percentage of the gap width remained after 20 hours of cell incubation in presence of DMSO as a vehicle control or simvastatin (8 μM) was plotted. All experiments were performed at least three times in duplicates; * = p<0.05; ** = p<0.01; *** = p<0.001.

Figure 4

Mesenchymal and epithelial markers in breast carcinoma cells treated with simvastatin. (A) Simvastatin-dependent regulation of vimentin and E-cadherin expressions in parental and radioresistant breast carcinoma cells were evaluated using Western blot analysis as described in the section Materials and Methods. IDV was calculated for each protein band and normalized to the α-tubulin band density after background correction. IDV ratio means fold-change of vimentin or E-cadherin band densities in simvastatin-treated compared to the vehicle-treated breast carcinoma cells. (B) 3D holographic breast cancer cell microscopy. Parental and radioresistant MDA-MB-231, T47D, and Au565 cells were analyzed for their morphology using 3D Nanolive Explorer-FLUO as described in the Materials and Methods.
Mesenchymal and epithelial markers in breast carcinoma cells treated with simvastatin. (A) Simvastatin-dependent regulation of vimentin and E-cadherin expressions in parental and radioresistant breast carcinoma cells were evaluated using Western blot analysis as described in the section Materials and Methods. IDV was calculated for each protein band and normalized to the α-tubulin band density after background correction. IDV ratio means fold-change of vimentin or E-cadherin band densities in simvastatin-treated compared to the vehicle-treated breast carcinoma cells. (B) 3D holographic breast cancer cell microscopy. Parental and radioresistant MDA-MB-231, T47D, and Au565 cells were analyzed for their morphology using 3D Nanolive Explorer-FLUO as described in the Materials and Methods.

Figure 5

Cell death development in breast carcinoma cells treated with simvastatin or irradiation or their combination. At indicated time points, analysis of sub-G1 cell fraction was evaluated in the samples collected after treatment of parental and radioresistant breast carcinoma cells with simvastatin (8 μM) alone, irradiation (2 Gy) alone or combination of simvastatin (8 μM) and irradiation (2 Gy). All experiments were performed at least three times in duplicates; * = p<0.05; ** = p<0.01; *** = p<0.001.
Cell death development in breast carcinoma cells treated with simvastatin or irradiation or their combination. At indicated time points, analysis of sub-G1 cell fraction was evaluated in the samples collected after treatment of parental and radioresistant breast carcinoma cells with simvastatin (8 μM) alone, irradiation (2 Gy) alone or combination of simvastatin (8 μM) and irradiation (2 Gy). All experiments were performed at least three times in duplicates; * = p<0.05; ** = p<0.01; *** = p<0.001.

Figure 6

Regulation of apoptosis- and autophagy-related proteins in breast carcinoma cells. Treatment-induced modulation of protein expression in parental and radioresistant breast carcinoma cells were investigated using Western blot analysis. Cells were either treated with simvastatin (8 μM), or irradiation alone at a dose of 2 Gy, or with combination treatment using simvastatin (8 μM) pretreatment (24 hours) followed by irradiation at a single dose of 2 Gy. Protein extractions were performed at the indicated time points, and then samples were analyzed using Western blotting as described in Materials and Methods.
Regulation of apoptosis- and autophagy-related proteins in breast carcinoma cells. Treatment-induced modulation of protein expression in parental and radioresistant breast carcinoma cells were investigated using Western blot analysis. Cells were either treated with simvastatin (8 μM), or irradiation alone at a dose of 2 Gy, or with combination treatment using simvastatin (8 μM) pretreatment (24 hours) followed by irradiation at a single dose of 2 Gy. Protein extractions were performed at the indicated time points, and then samples were analyzed using Western blotting as described in Materials and Methods.

Figure 7

3-hydroxy-3-methylglutharyl-coenzyme A reductase (HMGCR) expression and recurrence free survival in breast cancer patients. Prognostic value of the HMGCR expression at the mRNA level in breast cancer patients was evaluated using the KMplot database (http://kmplot.com/analysis/) and the results indicate that higher HMGCR expression was associated with worse overall survival in all cohorts of patients.
3-hydroxy-3-methylglutharyl-coenzyme A reductase (HMGCR) expression and recurrence free survival in breast cancer patients. Prognostic value of the HMGCR expression at the mRNA level in breast cancer patients was evaluated using the KMplot database (http://kmplot.com/analysis/) and the results indicate that higher HMGCR expression was associated with worse overall survival in all cohorts of patients.
eISSN:
1581-3207
Sprache:
Englisch
Zeitrahmen der Veröffentlichung:
4 Hefte pro Jahr
Fachgebiete der Zeitschrift:
Medizin, Klinische Medizin, Allgemeinmedizin, Innere Medizin, Hämatologie, Onkologie, Radiologie
Zeitschrift RSS Feed